nach oben

Drugs

Erschienen in:

01.07.2013 | Systematic Review

Efficacy and Safety of Botulinum Toxin A Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Review

verfasst von: Irina Soljanik

Erschienen in: Drugs | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Botulinum toxin A (BoNTA) is increasingly used for therapy of neurogenic detrusor overactivity (NDO) refractory to antimuscarinics or where patients are experiencing antimuscarinic-related side effects.

Objective

The objective was to compare and critically discuss the reported efficacy and safety of BoNTA in adults with neurogenic bladder dysfunction.

Data Sources

Studies published between January 1985 and July 2012 were identified in the MEDLINE (PubMed) and SCOPUS databases.

Study Selection, Study Appraisal and Synthesis Methods

A search for studies with onabotulinumtoxinA—the only formulation of BoNTA approved by the US FDA in adults with NDO—was performed. Exclusion criteria were urethral sphincter injection, no separate analysis between onabotulinumtoxinA and other formulations of BoNTA, mean follow-up ≤4 weeks and studies with ten or fewer patients. Clinical and urodynamic parameters for efficacy, adverse events (AEs) and tolerability were reviewed to offer recommendations for practice and future research.

Results

A total of 28 included studies revealed superior effects of onabotulinumtoxinA compared with placebo in achieving continence, reducing incontinence episodes, improving urodynamic parameters and health-related quality of life. The most frequently reported AEs were de novo intermittent catheterization, urinary retention and asymptomatic urinary infection.

Limitations

Limitations of this review are the inclusion of studies with the level-3 evidence (22/28 studies), the heterogenicity of outcome parameters and time points chosen for follow-up reported in the reviewed studies.

Conclusions

OnabotulinumtoxinA therapy is effective, safe and well tolerated in adults with neurogenic bladder dysfunction. Further high-quality prospective trial data are required to determine the optimal dose, injection technique, long-term safety, favourable timing, indications for re-injections, and the impact of concomitant antimuscarinics on onabotulinumtoxinA therapy.

Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49.PubMedCrossRef

Pannek J, Blok B, Castro-Diaz D, et al. Guidelines on neurogenic lower urinary tract dysfunction. In: Online Guidelines. European Association of Urology. 2013. http://www.uroweb.org/gls/pdf/20_Neurogenic%20LUTD_LR.pdf. Accessed Mar 2011.

Kerner J. Das Fettgift oder die Fettsäure und ihre Wirkungen auf den tierischen Organismus, ein Beitrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Stuttgart: Cotta; 1822.

van Ermengem E. Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Zeitsch Hyg Infekt. 1897;26:1–56.

Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(Suppl 1):S16–24.PubMedCrossRef

Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin a injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229–35.PubMedCrossRef

Ikeda Y, Zabbarova IV, Birder LA, et al. Botulinum neurotoxin serotype a suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol. 2012. doi:10.1016/j.eururo.2012.03.031.PubMed

Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.PubMedCrossRef

Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71:24–6.PubMed

10.

Stohrer M, Schurch B, Kramer G, et al. Botulinum A toxin in the treatment of detrusor hyperreflexia in spinal cord injury: a new alternative to medical and surgical procedures? Neurourol Urodyn. 1999;18:401–2.CrossRef

11.

Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7.PubMedCrossRef

12.

Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003;44:165–74.PubMedCrossRef

13.

Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53:275–87.PubMedCrossRef

14.

Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60:784–95.PubMedCrossRef

15.

Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011;(12):CD005493.

16.

Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55:100–20.PubMedCrossRef

17.

Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–9.PubMedCrossRef

18.

Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742–50.PubMedCrossRef

19.

Wefer B, Ehlken B, Bremer J, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol. 2010;28:385–90.PubMedCrossRef

20.

Reitz A, Stöhrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45:510–5.PubMedCrossRef

21.

Bagi P, Biering-Sørensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol. 2004;38:495–8.PubMedCrossRef

22.

Giannantoni A, Mearini E, Del Zingaro M, et al. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55:705–11.PubMedCrossRef

23.

Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder—to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184:2423–8.PubMedCrossRef

24.

Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004;172:240–3.PubMedCrossRef

25.

Gomes CM, Castro Filho JE, Rejowski RF, et al. Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity. Int Braz J Urol. 2010;36:66–74.PubMedCrossRef

26.

Grosse J, Kramer G, Jakse G. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. BJU Int. 2009;104:651–6.PubMedCrossRef

27.

Kalsi V, Popat RB, Apostolidis A, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol. 2006;49:519–27.PubMedCrossRef

28.

Kuo HC, Liu SH. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries. Neurourol Urodyn. 2011;30:1541–5.PubMedCrossRef

29.

Kuo HC. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection. Urology. 2008;72:1056–60.PubMedCrossRef

30.

Conte A, Giannantoni A, Proietti S, et al. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. Eur J Neurol. 2012;19:725–32.PubMedCrossRef

31.

Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol. 2006;175:2341–4.PubMedCrossRef

32.

Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174:984–9.PubMedCrossRef

33.

Tow AM, Toh KL, Chan SP, et al. Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore. Ann Acad Med Singap. 2007;36:11–7.PubMed

34.

Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol. 2010;184:2578–85.PubMedCrossRef

35.

Pannek J, Göcking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int. 2009;104:1246–50.PubMedCrossRef

36.

Deffontaines-Rufin S, Weil M, Verollet D, et al. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol. 2011;37:642–8.PubMedCrossRef

37.

Huwyler M, Schurch B, Knapp PA, et al. Can the ice-water test predict the outcome of intradetrusor injections of botulinum toxin in patients with neurogenic bladder dysfunction? World J Urol. 2007;25:613–7.PubMedCrossRef

38.

Reitz A, Denys P, Fermanian C, et al. Do repeat intradetrusorbotulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol. 2007;52:1729–35.PubMedCrossRef

39.

Schulte-Baukloh H, Schobert J, Stolze T, et al. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn. 2006;25:110–5.PubMedCrossRef

40.

Caremel R, Courtois F, Charvier K, et al. Side effects of intradetrusorbotulinum toxin injections on ejaculation and fertility in men with spinal cord injury: preliminary findings. BJU Int. 2012;109:1698–702.PubMedCrossRef

41.

Mouttalib S, Khan S, Castel-Lacanal E, et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int. 2010;106:1677–80.PubMedCrossRef

42.

Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40:599–600.PubMedCrossRef

43.

Khan S, Game X, Kalsi V, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185:1344–9.PubMedCrossRef

44.

Chen CY, Liao CH, Kuo HC. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia. Spinal Cord. 2011;49:659–64.PubMedCrossRef

45.

Chen G, Liao L. Injections of botulinum toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury. Int Urol Nephrol. 2011;43:655–62.PubMedCrossRef

46.

Moore KM, Hirst G, Emery S, et al. Double blind, placebo controlled, randomised, cross over study of trigone specific injections of botulinum toxin B for treating patients with idiopathic detrusor overactivity refractory to other conservative treatments (Abstract number 209). Neurourol Urodyn. 2009;28:833–4.

47.

Gamé X, Khan S, Panicker JN, et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU. 2010;107:1786–92.

48.

Gamé X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53:613–8.PubMedCrossRef

49.

Andersson KE. Bladder activation: afferent mechanisms. Urology. 2002;59:43–50.PubMedCrossRef

Titel: Efficacy and Safety of Botulinum Toxin A Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Review
verfasst von: Irina Soljanik
Publikationsdatum: 01.07.2013
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 10/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-013-0068-5

Springer Medizin

Abstract

Background

Objective

Data Sources

Study Selection, Study Appraisal and Synthesis Methods

Results

Limitations

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2013

Intermittent Claudication: New Targets for Drug Development

Ceftaroline Fosamil: A Review of its Use in the Treatment of Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia

Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis

Vaccine Development for Tuberculosis: Current Progress

Crofelemer: A Review of its Use in the Management of Non-Infectious Diarrhoea in Adult Patients with HIV/AIDS on Antiretroviral Therapy

A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs